by Annette Pinder According to KFF News, new research suggests that patients with colon cancer who have a history of treatment with glucagon-like peptide-1 (GLP-1) receptor agonists may have a significantly higher 5-year survival rate than those who do not
Freisthler B, Wernekinck U
File File history File usage on Commons File usage on other wikis Metadata Original file (932 1,080 pixels, file size: 540 KB, MIME type: image/png) File information Structured data Captions Captions Add a one-line explanation of what this file represents I, the copyright holder of this work, hereby publish it under the following license: You are free: to share to copy, distribute and transmit the work to remix to adapt the work Under the following conditions: attribution You must give appropriate credit, provide a link to the license, and indicate if changes were made
April 1, 2026: More People File Lawsuits Against GLP-1 Drugs Like Trulicity As of April 1, 2026, there are 3,546 pending lawsuits in MDL 3094
Setting Realistic Expectations for 2026 What Clinical Data Shows According to clinical trial data for FDA-approved tirzepatide, participants experienced a range of weight loss outcomes over 72-week study periods
Start Your Semaglutide Journey Today
